Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,622,097
  • Shares Outstanding, K 63,809
  • Annual Sales, $ 46,020 K
  • Annual Income, $ -130,150 K
  • EBIT $ -158 M
  • EBITDA $ -162 M
  • 60-Month Beta 2.12
  • Price/Sales 143.76
  • Price/Cash Flow N/A
  • Price/Book 10.54

Options Overview Details

View History
  • Implied Volatility 49.10% (+3.51%)
  • Historical Volatility 42.86%
  • IV Percentile 48%
  • IV Rank 36.86%
  • IV High 72.20% on 04/10/25
  • IV Low 35.62% on 11/17/25
  • Expected Move (DTE 11) 7.23 (7.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 287
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 7,379
  • Open Int (30-Day) 6,668
  • Expected Range 96.02 to 110.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.65
  • Number of Estimates 5
  • High Estimate $-0.25
  • Low Estimate $-0.81
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) -242.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
90.58 +14.20%
on 03/18/26
107.84 -4.08%
on 04/01/26
+11.35 (+12.32%)
since 03/06/26
3-Month
77.00 +34.34%
on 02/23/26
107.84 -4.08%
on 04/01/26
+21.17 (+25.73%)
since 01/06/26
52-Week
39.60 +161.21%
on 04/09/25
107.84 -4.08%
on 04/01/26
+59.00 (+132.76%)
since 04/04/25

Most Recent Stories

More News
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis

PTGX : 102.47 (-1.26%)
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill

PTGX : 102.47 (-1.26%)
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study ...

PTGX : 102.47 (-1.26%)
TAK : 18.31 (-2.29%)
Protagonist Therapeutics: Q4 Earnings Snapshot

Protagonist Therapeutics: Q4 Earnings Snapshot

PTGX : 102.47 (-1.26%)
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.)

PTGX : 102.47 (-1.26%)
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year

PTGX : 102.47 (-1.26%)
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026

NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will...

PTGX : 102.47 (-1.26%)
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will...

PTGX : 102.47 (-1.26%)
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera ...

PTGX : 102.47 (-1.26%)
TAK : 18.31 (-2.29%)
Breakthrough ASH Data Drives Blood Cancer Market To $240B Valuation

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...

PTGX : 102.47 (-1.26%)
KPTI : 6.24 (+5.94%)
GTBP : 0.4443 (-1.16%)
GSK : 56.65 (-0.07%)
TAK : 18.31 (-2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 107.58
2nd Resistance Point 105.95
1st Resistance Point 104.86
Last Price 102.47
1st Support Level 102.14
2nd Support Level 100.51
3rd Support Level 99.42

See More

52-Week High 107.84
Last Price 102.47
Fibonacci 61.8% 81.77
Fibonacci 50% 73.72
Fibonacci 38.2% 65.67
52-Week Low 39.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.